OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.610
+0.010 (0.63%)
At close: Oct 1, 2026, 4:00 PM EDT
1.610
0.00 (0.00%)
After-hours: Oct 1, 2026, 6:30 PM EDT
OS Therapies Employees
As of December 31, 2025, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,873,916
Market Cap
74.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 4 | 1 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 4 | 1 |
| Mar 31, 2024 | 4 | 0 | - | 3 | 1 |
| Sep 30, 2023 | 4 | 0 | - | 3 | 1 |
| Mar 31, 2023 | 4 | - | - | 3 | 1 |
| Dec 31, 2022 | 4 | - | - | 3 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Adicet Bio | 102 |
| Fortress Biotech | 78 |
| Verrica Pharmaceuticals | 76 |
| Connect Biopharma Holdings | 64 |
| Spero Therapeutics | 25 |
| iBio, Inc. | 23 |
| Gain Therapeutics | 21 |
OSTX News
- 10 hours ago - OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer - Newsfile Corp
- 7 days ago - OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) - Newsfile Corp
- 10 days ago - OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis - Newsfile Corp
- 14 days ago - OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program - Newsfile Corp
- 16 days ago - OS Therapies announces full alignment on UK authorization application - TheFly
- 16 days ago - OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing - Newsfile Corp
- 23 days ago - OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial - Newsfile Corp
- 4 weeks ago - OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance - Newsfile Corp